RecruitingRecruiting
Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder
NCT07226661 · Supernus Pharmaceuticals, Inc.
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SPN-821 as an Adjunctive Therapy in Adults With Major Depressive Disorder
About this study
This is a multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of SPN-821 administered twice a week as adjunctive therapy to an approved antidepressant therapy in adult participants with MDD. The study includes a 2-week Screening Period, a 4-week Double blind Treatment Period, and a Safety Follow-up phone call one week after the completion of the Treatment Period.
Eligibility criteria
Inclusion Criteria:
* Current diagnosis of MDD according to the DSM-5 for either single or recurrent MDE without psychotic features confirmed by the MINI
* Duration of current MDE of at least 8 weeks
* MADRS total score of ≥ 24 at the Screening Visit and Day 1 Visit
* CGI-S score of ≥ 4 (moderately ill or worse) at the Screening Visit and Day 1 Visit
* Stable, therapeutic dose of one of the following protocol-approved ADTs as a monotherapy for ≥ 8 weeks before the Screening Visit and ≥ 10 weeks at the Day 1 Visit. Additionally, inadequate response to the current ADT (less than 50% improvement in depressive symptoms) as confirmed by the ATRQ Investigator administered.
Exclusion Criteria:
* MADRS total score change of ≥ 25% from the Screening Visit to Day 1 Visit
* History of treatment resistant depression (TRD) defined as 3 or more failed ADTs of adequate dose (per ATRQ) and duration (at least 8 weeks) for the current MDE
* History of alcohol or substance use disorder according to DSM-5 criteria 6 months before the Screening Visit
* Evidence of significant risk for suicidal behavior during participation in the study in the Investigator's opinion
* Lifetime diagnosis of any psychotic disorder including MDD with psychosis, MDD with mixed features, bipolar I/II disorder, bipolar depression, schizophrenia, posttraumatic stress disorder, autism spectrum disorder, or any personality disorder or intellectual disability that would affect the ability of the participant to enroll in the study
* Diagnosis less then 12 months before screening of severe obsessive-compulsive disorder, acute stress disorder, panic disorder, eating disorders, or any other psychiatric condition that has been the primary focus of treatment, or diagnosis of generalized anxiety disorder less then 6 months before screening.
* History of cardiovascular, respiratory, gastrointestinal, renal, hepatic, and hematologic disorders, or other medical disorders that could impose undue risk or compromise the study in the Investigator's opinion
* Clinically significant abnormal result prior to Day 1 Visit per Investigator's judgment or abnormal renal function.
* Requires treatment with a medication or other substance that is prohibited by the protocol.
Study design
Enrollment target: 230 participants
Allocation: randomized
Masking: triple
Age groups: adult, older_adult
Timeline
Starts: 2026-01-19
Estimated completion: 2027-01-31
Last updated: 2026-11-16
Interventions
Drug: SPN-821 2400 mgDrug: Placebo
Primary outcomes
- • Change From Baseline to Day 29 in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score. (4 weeks)
Sponsor
Supernus Pharmaceuticals, Inc. · industry
Contacts & investigators
ContactGianpiera Ceresoli-Borroni, PhD · contact · clinicaltrials@supernus.com · 301-838-2500
All locations (40)
University of AlabamaRecruiting
Birmingham, Alabama, United States
IMA Clinical Research PhoenixRecruiting
Phoenix, Arizona, United States
Woodland Research Northwest (ERG)Recruiting
Rogers, Arkansas, United States
Inland Psychiatric Medical GroupRecruiting
Chino, California, United States
Leading Edge Research (Eximia Network)Recruiting
Encino, California, United States
Cenexel Collaborative Neuroscience NetworkRecruiting
Garden Grove, California, United States
Synergy Research (ERG Network)Recruiting
Lemon Grove, California, United States
Catalina Research Institute (Elixia)Recruiting
Montclair, California, United States
ATP Clinical ResearchRecruiting
Orange, California, United States
NRC Research InstituteRecruiting
Orange, California, United States
Lumos Clinical Research CenterRecruiting
San Jose, California, United States
Inland Psychiatric Medical GroupRecruiting
Temecula, California, United States
Mountain View Clinical ResearchRecruiting
Denver, Colorado, United States
CT Clinical ResearchRecruiting
Cromwell, Connecticut, United States
CNS Healthcare - JacksonvilleRecruiting
Jacksonville, Florida, United States
Avantis Clinical ResearchRecruiting
Miami, Florida, United States
CNS Healthcare of OrlandoRecruiting
Orlando, Florida, United States
Space Coast Neuropsychiatric Research InstituteRecruiting
Palm Bay, Florida, United States
Cenexel TampaRecruiting
Tampa, Florida, United States
Interventional Psychiatry of Tampa BayRecruiting
Tampa, Florida, United States
Cenexel Atlanta (ACMR)Recruiting
Atlanta, Georgia, United States
Cenexel iResearch AtlantaRecruiting
Decatur, Georgia, United States
AMR Conventions ResearchRecruiting
Warrenville, Illinois, United States
Precise Clinical ResearchRecruiting
Flowood, Mississippi, United States
Psychiatric Care and Research CenterRecruiting
O'Fallon, Missouri, United States
Midwest Research GroupRecruiting
Saint Charles, Missouri, United States
Vector Clinical TrialsRecruiting
Las Vegas, Nevada, United States
Cenexel Marlton (HRI)Recruiting
Marlton, New Jersey, United States
SPRI Clinical TrialsRecruiting
Brooklyn, New York, United States
Manhattan Behavioral MedicineRecruiting
New York, New York, United States
New Hope Clinical ResearchRecruiting
Charlotte, North Carolina, United States
Paradigm Research ProfessionalsRecruiting
Oklahoma City, Oklahoma, United States
Summit Headlands (Headlands Research)Recruiting
Portland, Oregon, United States
Houston Clinical TrialsRecruiting
Bellaire, Texas, United States
Baylor College of MedicineRecruiting
Houston, Texas, United States
DM ClinicalRecruiting
Houston, Texas, United States
Grayline Research CenterRecruiting
Wichita Falls, Texas, United States
Alpine Research OrganizationRecruiting
Clinton, Utah, United States
Aura WellnessRecruiting
Salt Lake City, Utah, United States
Core Clinical ResearchRecruiting
Everett, Washington, United States